---
title: "CSL Posts Loss In FY26 On Restructuring Costs, Impairments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296181246.md"
description: "CSL Limited reported a net loss of $2.6 billion for FY2026 due to $7.1 billion in pre-tax impairments and restructuring costs, despite underlying NPATA of $3.1 billion. Revenue rose to $15.8 billion. The company forecasts FY2027 revenue stability and ~5% underlying profit growth, alongside a $1.5 billion US plasma expansion plan. Shares rose 17.36%."
datetime: "2026-08-18T05:43:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296181246.md)
  - [en](https://longbridge.com/en/news/296181246.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296181246.md)
generator: "portal-rs"
---

# CSL Posts Loss In FY26 On Restructuring Costs, Impairments

Add  as your preferred news source on Google

 Add Now

CSL Limited (CSL.AX) reported underlying net profit after tax to shareholders of $3.1 billion for the 12 months ended 30 June 2026, down 2% from last year. Underlying NPATA earnings per share was $6.43 compared to $6.65. After one-off restructuring costs and impairments, the company reported a net loss after tax to shareholders of $2.6 billion. Statutory per share result was a loss of $5.35 compared to profit of $6.20. The company recognised pre-tax impairments of $5.5 billion in the second half of fiscal year, resulting in total pre-tax impairments of $7.1 billion in fiscal 2026. Total revenue was $15.80 billion compared to $15.56 billion, last year. 

In fiscal 2027, CSL expects revenue to be in line with the prior year and underlying net profit after tax growth of approximately 5%.

CSL also announced its intention to spend approximately $1.5 billion to expand its U.S. plasma manufacturing presence, which includes the Horizon 2 yield improvement program.

CSL shares are trading at A$157.96 on Australian Securities Exchange, up 17.36%. 

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md)
- [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md)

## Related News & Research

- [Ord Minnett Remains a Hold on CSL (CMXHF)](https://longbridge.com/en/news/297715214.md)
- [CSL Enters Agreements With U.S. Government To Lower Drug Prices](https://longbridge.com/en/news/297553911.md)
- [CSL signs U.S. government agreements to lower drug prices for Medicaid](https://longbridge.com/en/news/297567342.md)
- [CSL: Significant impairments led to a net loss, but cost savings and strong cash flow support future growth](https://longbridge.com/en/news/296150629.md)
- [Rare-Disease Drug Tavneos Faces UK Withdrawal](https://longbridge.com/en/news/297819339.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**